Moderna vaccine 94.5% effective in second breakthrough

Modesto Morganelli
Ноября 21, 2020

Indian government is in dialogue with USA biotech giant Moderna, regarding initial successful development of its COVID-19 vaccine candidate, which the drugmaker on Monday announced had achieved 94.5 per cent efficacy in phase 3 trials.

Crucially, Moderna also announced that its vaccine can remain stable at standard refrigerator temperatures of 2 degrees Celsius to 8 degrees Celsius for 30 days.

It is not yet clear how long lasting the protection will be from either the Moderna or Pfizer vaccines, nor how well they work for the elderly, the age-group at highest risk from COVID-19.

Anthont Fauci, America's top infectious diseases expert, called the Moderna results "striking".

The company added it could be kept in long-term storage at standard freezer temperatures of -20 degrees Celsius for up to six months.

After the US biotech company Moderna on Monday announced significant interim results of its Covid-19 vaccine, the White House credited US President Donald Trump for the progress of the vaccine which has been shown to be 94.5 per cent effective for the treatment of coronavirus.

Moderna's vaccine candidate, created in collaboration with the National Institutes of Health, has 30,000 volunteers in its fold. Side effects from the clinical trial vaccine, for now, appear minimal.

According to the company, 90 of the participants who got infected with Covid-19 are from the placebo group while only 5 cases of infection were seen in the group that received two doses of the vaccine.

Another bright spot: All 11 "severe cases" occurred in the placebo group and none in the mRNA-1273 vaccinated group.

This announcement followed announcements by U.S. giant Pfizer and Germany's BioNTech who said their vaccine, was found to be more than 90 per cent effective.

Moderna intends to submit for an Emergency Use Authorization (EUA) with the US Food and Drug Administration (FDA) in the coming weeks.

MENAFN provides the information "as is" without warranty of any kind.

Altre relazioni

Discuti questo articolo

Segui i nostri GIORNALE